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AbstrAct
introduction: There is an epidemic of chronic kidney disease (CKD) in Africa and human immunodeficiency virus 
(HIV) infection is among the major drivers. However, the burden of CKD in HIV-infected patients in Africa varies 
widely by country and study, ranging from 0.5–59.3%. Published data on the prevalence of CKD in the Namibian 
HIV-infected population are scarce. In this study, we aimed to estimate the prevalence of CKD and associated factors 
in HIV-infected adults on antiretroviral therapy in northern Namibia.
Methods: We conducted a cross-sectional study in the four regions of northern Namibia, using existing electronic 
records used in the management of HIV-infected patients. Variables captured included the two most recent serum 
creatinine measurements, date of birth, sex, date of initiating antiretroviral therapy, current antiretroviral treatment, 
and most recent HIV viral load results. We used standardised serum creatinine measurements to estimate the 
glomerular filtration rate (GFR) using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. 
CKD was defined as estimated GFR (eGFR) < 60 mL/min/1.73 m2 on two occasions at least three months apart. 
Factors associated with CKD were assessed using logistic regression.
results: We included 1 993 participants, of whom 1 362 (68%) were female and  mean age was 44.5 ± 11.5 years. 
The proportion of participants who were virally suppressed was 97% (95% CI 96, 98%) and the median duration 
on antiretroviral therapy was 107 months (IQR 62–149). The prevalence of CKD was 1.4% (95% CI 1.0, 2.0%). 
CKD cases were 13 times more likely to be 45 years or older and 3.5 times more likely to be male than those 
without CKD.
conclusions: Our findings suggest a low prevalence of CKD among the HIV-infected population in northern 
Namibia. Patients older than 45 years may need additional monitoring for kidney function using eGFR.
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INtrODUctION
Chronic kidney disease (CKD) is a condition characterized 
by abnormalities of kidney function or kidney structure, 
that have been present for at least 3 months, with impli-
cations for health [1]. The consequences of CKD include 
the development of kidney failure and a 30-fold increase 
in cardiovascular disease mortality in patients with CKD 
compared to the general population [2]. Symptoms of 
CKD are non-specific or absent until the disease is 
advanced [3]. This makes screening essential for earlier 
diagnosis and intervention to improve outcomes. The 
diagnosis and classification of CKD is based on measure-
ment of markers of kidney damage such as persistent 
proteinuria, estimation of the glomerular filtration rate 
(GFR), and radiological imaging for abnormal kidney 
structure [3,4]. 
Prediction equations are used to estimate the GFR from 
measurements of serum creatinine and current guidelines 
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recommend the use of the Chronic Kidney Disease 
Epidemiology Collaboration (CKD-EPI) equation [1]. 
Methods used to estimate GFR have an important influence 
on the diagnosis of CKD, the stage of CKD, and the 
reported burden of CKD [4]. Variation in creatinine assays 
may lead to interlaboratory variations in serum creatinine 
measurements and, in turn, estimated GFR (eGFR). Hence, 
measurement and reporting of standardized serum creati-
nine is recommended, where the assay is calibrated to 
isotope dilution mass spectrometry (IDMS)-traceable refe-
rence materials. An eGFR of less than 60 mL/min/1.73 m2 
for at least 3 months is used as the threshold to diagnose 
CKD [1]. 
There is an epidemic of CKD in Africa that is being driven 
by diseases such as diabetes mellitus and hypertension, 
human immunodeficiency virus (HIV) infection, pregnancy 
complications, use of herbal or traditional medicines and 
trauma [4,5]. Diabetic nephropathy is a common com-
plication of diabetes mellitus that may result in CKD, and 
its occurrence is increasing in Africa [6]. Hypertension is 
reported to be an important cause of CKD, though it can 
occur secondary to pre-existing kidney disease [7]. Sub-
Saharan Africa is the region most affected by HIV infection, 
with 26 million people living with HIV. Highly active anti-
retroviral therapy has greatly improved the survival of HIV-
infected people [8]. This improved survival has resulted in 
HIV infection occurring in the presence of noncommuni-
cable diseases, leading to an elevated risk of CKD among 
HIV-infected patients [8,9]. Further-more, infection with 
HIV and treatment with certain antiretroviral medicines has 
been associated with kidney pathology such as glomerular 
damage, tubular injury, and chronic inflammation [10]. 
HIV-infected patients develop CKD due to HIV-associated 
nephropathy (HIVAN), HIV-related immune complex 
disease, chronic inflammation, or subsequent to acute 
kidney injury (AKI) associated with opportunistic infections 
or medicine toxicity [2,10]. Tenofovir disoproxil fumarate 
(TDF) is a reverse transcriptase inhibitor used in the treat-
ment of HIV infection. TDF-related kidney injury is more 
likely in patients with pre-existing kidney impairment, 
advanced HIV disease, diabetes mellitus, hypertension, hep-
atitis B coinfection and concurrent use of nephrotoxic 
medicines [4,10]. Genetic susceptibility due to poly-
morphisms in the apolipoprotein L1 (APOL1) gene puts 
individuals of African descent particularly at risk of 
CKD [2,10]. 
CKD in the HIV-infected population leads to poor oucomes, 
including an increase in mortality [11]. In a study conducted 
in South Africa, kidney disease was an important risk factor 
for increased in-hospital mortality among HIV-infected 
patients [12]. Additionally, inadequate monitoring of kidney 
function was recognized as a modifiable risk factor con-
tributing to elevated mortality in HIV-infected adults in 
Namibia [13]. If CKD progresses to kidney failure, lifesaving 
kidney replacement therapy (KRT) or kidney transplanta-
tion will be required. However, there are marked dispari-
ties in access to KRT, especially among African countries. 
The burden of HIV-associated kidney disease varies widely 
by country in Africa, and ranges from 0.5% to 59.3% 
[5,14-16]. Part of this variation is thought to be a result of 
varying methods used to assess kidney function, differences 
in the definition of kidney disease and in the equations used 
to estimate the GFR [5]. Many studies use only a single 
eGFR estimate to assess CKD prevalence, leading to over-
estimation of the burden of disease [14]. There are con-
cerns that an epidemic of HIV-associated CKD may go 
unrecognized due to the lack of good quality data from 
sub-Saharan Africa [8]. As such, reviews conducted on 
CKD prevalence in Africa have concluded that there is a 
need to generate good quality prevalence data on CKD in 
HIV from sub-Saharan Africa [5,14,15]. 
Namibia is a country in southern Africa with an estimated 
population of 2.5 million people, divided into 14 regions, 
and is classified as an upper-middle-income country by the 
World Bank. The country has a high burden of HIV infec-
tion, with an estimated prevalence of 12.6% among those 
aged from 15 to 64 years [17]. HIV prevalence is highest in 
the Zambezi region at 22.3%, followed by the four regions 
of northern Namibia, ranging from 15.8% to 17.9% [17]. 
Guidelines for the management of HIV infection have been 
produced, which recommend laboratory monitoring of 
kidney function as part of the standard care [18]. The 
country’s guidelines recommend the use of creatinine 
clearance as an indicator of kidney function and it is esti-
mated based on serum creatinine measurements using the 
Cockcroft–Gault equation [18]. Kidney function is assessed 
at baseline, 6 weeks from baseline, 6 and 12 months from 
baseline, and annually thereafter [18]. However, routine 
monitoring for persistent proteinuria is not performed. 
Despite the high burden of HIV infection, there is a lack 
of published data on the prevalence of CKD among 
HIV-infected adults in Namibia. Considering the potential 
disease burden, the high cost of treatment for kidney fail-
ure, and disparities in the availability of KRT, it is important 
to determine the prevalence of CKD associated with HIV 
infection and the related risk factors. 
The main objective of the study was to estimate the pro-
portion of patients with CKD among HIV-infected adults 
on antiretroviral therapy. The secondary objective was to 
assess the demographic and clinical factors associated with 
CKD in this population.
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MEtHODs
We carried out a cross-sectional study where data were 
obtained from the electronic database used in the manage-
ment of HIV-infected patients in the public healthcare 
sector in Namibia. A retrospective record review of elec-
tronically available datasets was carried out at hospitals in 
the Ohangwena, Omusati, Oshana and Oshikoto regions 
of northern Namibia. Participating hospitals were Eenhana 
and Engela District Hospitals in Ohangwena region, 
Oshikuku and Outapi District Hospitals in Omusati region, 
Oshakati Intermediate Hospital in Oshana region, and 
Onandjokwe Intermediate Hospital in Oshikoto region. 
The antiretroviral therapy electronic patient monitoring 
system (ART EPMS) was established in 2007 and is the 
main electronic reporting system for HIV patient care in 
Namibia. The platform is owned by the Ministry of 
Health and Social Services (MOHSS) of the Republic of 
Namibia. The EPMS was based at public sector facilities 
offering HIV care and the sources of the data are the HIV 
patient care booklets and registers. Data comprising patient 
demographics, date of entry into care, laboratory test 
results, treatment regimen, and appointments are recorded 
by healthcare workers at the point of care in the HIV care 
booklets and registers. The data are then transcribed by 
data clerks into the electronic database, where periodic 
reports are generated in electronic form, and relayed to 
regional and national levels for data cleaning, aggregation 
and analysis. For our study, the closing date for data 
collection was 20 November 2020. 
The study population was HIV-infected adults on anti-
retroviral therapy in the four regions of northern Namibia. 
For inclusion in the study, participants had to be women 
and men of 18 years and older, on antiretroviral therapy, to 
have had at least two measurements of serum creatinine 
that were at least three months apart, and attending HIV 
care clinics in Ohangwena, Omusati, Oshana and Oshikoto 
regions. Serum creatinine measurements obtained earlier 
than 1 January 2017 were not considered. For recruitment, 
at each hospital a status report of active patients registered 
for HIV management was generated from the electronic 
database and exported to Microsoft Excel. Active patients 
were defined as those who would have received treatment 
at the site within a period of three months up to the point 
of data collection; routine appointments are three 
months apart. 
Thereafter, a random sample of patients was selected in 
Microsoft Excel using the simple random selection function, 
and the required data extracted from the electronic 
database for each selected participant according to the 
data collection tool. The data collection tool was piloted 
on 50 participants and modified accordingly. Selected 
participants who did not satisfy the eligibility criteria were 
excluded. The required sample size to estimate the pre-
valence with minimum random error was calculated as 
follows: 95% confidence interval with a half width of 1%, 
estimated prevalence from the literature of 7% [14], there-
fore the required sample size was approximately 2 500 
participants using the formula for a single proportion. 
The two most recent serum creatinine measurements 
obtained at least three months apart, date of birth, sex, 
date of initiation of antiretroviral therapy, current anti-
retroviral treatment, and most recent HIV viral load results 
were the variables used in the study. Serum creatinine was 
measured by the Namibia Institute of Pathology (NIP) at 
laboratories located at the participating hospitals. The NIP 
reports standardized creatinine and uses National Institute 
of Standards and Technology standard reference material 
967a and the liquid chromatography IDMS reference 
method for calibration. The machines use the Jaffe method. 
STATA 16.1 was used for data analysis. The CKD-EPI equa-
tion was used to calculate the eGFR for the two serum 
creatinine results per participant [19]. Frequency, relative 
frequency (%), and 95% confidence intervals were used to 
estimate the prevalence of chronic disease using an eGFR 
of less than 60 mL/min/1.73 m2 for at least 3 months as the 
threshold to diagnose CKD. Age, sex and CKD were also 
assessed by region. The variables age greater than or equal 
to 45 years and duration on antiretroviral therapy greater 
than or equal to 108 months were generated based on the 
mean age and median duration cut points, respectively. 
Only four variables were assessed for association with 
CKD. These were chosen based on clinical importance in 
the literature. All four variables were assessed at univari-
able level for association with CKD at the 0.2 level of 
significance, and those variables which were associated at 
this level were added to a multiple logistic regression 
model. The model was assessed using the Hosmer–
Lemeshow test and the area under the receiver operating 
characteristics curve. 
Ethics considerations
The Health Research Ethics Committee (HREC) of the 
University of Stellenbosch approved the study with a 
waiver of informed consent (HREC reference number: 
S20/04/108). The MOHSS of Namibia and the NIP gave 
approval for the study as required by local regulations. 
rEsULts
A total of 1 993 participants were included in this study. 
The participant flow is shown in Figure 1. Women con-
stituted about 68% of participants, with Omusati region 
having the lowest proportion of women at 59% compared 
to the other regions. The mean age of participants was 44.5 
± 11.5 years. Table 1 shows the distribution of age and sex 
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by region. Oshana region had the oldest participants on 
average compared to the three other regions. The median 
duration of antiretroviral therapy use was 107 months with 
an interquartile range of 62 to 149 months.
The proportion of patients who were virally suppressed 
was 97.0% (95% CI 96.5, 98.0%), and those who had a 
history of using antiretroviral therapy including TDF were 
94.0% (95% CI 93.0, 95.1%). There were 28 patients with 
both eGFR measurements below 60 mL/min/1.73 m2, 
yielding a prevalence of CKD of 1.4% (95% CI 1.0, 2.0%). 
Participants with an initial eGFR less than 60 mL/min/ 
1.73 m2 were 2.6% (95% CI 2.0, 3.4%), while those with a 
later eGFR less than 60 mL/min/1.73 m2 were 2.8% (95% 
CI 2.1, 3.6%).
Table 2 shows the prevalence of CKD by region, with the 
Oshikoto region having the highest occurrence of CKD 
compared to the other regions, though the values are all 
quite low. There was no statistically significant difference in 
prevalence of CKD by region; chi-squared statistic 3.0 and 
P value 0.4.
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table 1.  characteristics of participants. 














Overall 1993 1362 (68.3) 631 (31.7) 44.5  11.5 107 (62–149) 97.3 (96.5–98) 94.1 (93–95.1)
Ohangwena 245 186 (75.9) 59 (24.1) 44  12.1 94 (46–145) 97.6 (94.8–99.1) 96.7 (93.7–98.6)
Omusati 450 267 (59.3) 183 (40.7) 40.8  11.7 92 (34–153) 96.0 (93.8–97.6) 97.1 (95.1–98.5)
Oshana 670 474 (70.7) 196 (29.3) 46.4  10.6 118 (76-146) 98.8 (97.7–100) 89.4 (86.8–91.6)
Oshikoto 628 435 (69.3) 193 (30.7) 45.5  11.5 105 (66–148) 96.7 (94.9–97.9) 96.0 (94.2–97.4)
ART, antiretroviral therapy; CI, confidence interval; cps/mL, copies per millilitre; IQR, interquartile range; N, number; SD, standard deviation; TDF, tenofovir disoproxil fumarate.
Figure 1.  Flowchart of participant selection process.
Screened for eligibility (total n = 2 625; Ohangwena = 284, Omusati = 581,  
Oshana = 1 114, Oshikoto = 646)
Patients in database at  
start of study (N = 80 552)
included (total n = 1 993; Ohangwena = 245, Omusati = 450, Oshana = 670, Oshikoto = 628)
excluded (total n = 632; Ohangwena = 39,  
Omusati = 131, Oshana = 444, Oshikoto = 18)
no cKD 
(n = 1 965)
cKD
(n = 28)
reasons for exclusion: 
35 were children
159 lacked creatinine results
293 had a single creatinine result
141 had creatinine results older than 2017
1 had creatinine results <3 months apart, and 
3 had no documented dates of birth.
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Table 3 shows the results of the crude analysis of risk 
factors for CKD. Age equal to or greater than 45 years 
[crude odds ratio (COR) 14.3 (95% CI 3.4, 60.5)] and male 
sex [COR 4 (95% CI 1.8, 8.7)] were risk factors. Viral load 
≥1000 copies/mL and duration of treatment ≥108 months 
were not associated with CKD.
The results of the multivariable analysis are shown in 
Table 4. Being 45 years or older was significantly associ-
ated with chronic kidney disease, after adjusting for sex 
[adjusted odds ratio (AOR) 13.2 (95% CI 3.1, 56.0)]. 
Participants with CKD were 13 times more likely to be 45 
years or older than those with no CKD. Similarly, male sex 
was significantly associated with CKD [AOR 3.5 (1.6, 7.7)]. 
Therefore, patients with CKD were 3.5 times more likely to 
be male than those without CKD. Viral load and duration 
of treatment were not significantly associated with chronic 
kidney disease, after adjusting for age and male sex and 
were thus excluded from the final model.
DIscUssION
The prevalence of CKD in this study of HIV-infected 
adults from northern Namibia was 1.4%. This is lower than 
the prevalence reported in systematic reviews on CKD in 
the HIV-infected population in Africa [5,14,15,20]. We 
found that age ≥45 years and being male were risk factors. 
Having a viral load ≥1000 copies/mL and longer duration 
on antiretroviral therapy were not associated with CKD in 
our study. 
The occurrence of CKD in HIV-infected populations in sub-
Saharan Africa varies by country, study, equation used to 
estimate GFR, and criteria for diagnosing CKD [14,15, 
21-23]. The prevalence tends to be higher when using a 
broader definition of CKD that includes albuminuria, eGFR, 
and structural kidney abnormalities compared to eGFR 
alone [21-24]. Many studies do not establish chronicity but 
rather rely on the exclusion of an acute illness that can be 
a cause of kidney disease during the period when kidney 
function is assessed [4,15]. In this study, we established 
chronicity by using two consecutive estimates of GFR that 
were at least three months apart. Furthermore, we calcu-
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table 2.  Prevalence of chronic kidney disease.
  cKD, n (total); % (95% ci)
Overall (1993) 28 (1993) 1.4% (1.0, 2.0)
Ohangwena (245) 4 (245) 1.6% (0.5, 4.1)
Omusati (450) 3 (450) 0.7% (0.1, 1.9)
Oshana (670) 9 (670) 1.3% (0.6, 2.5)
Oshikoto (628) 12 (628) 1.9% (1.0, 3.3)
CI, confidence interval; CKD, chronic kidney disease; N, number.
table 4.  Multivariable logistic regression analysis of patient 
characteristics on occurrence of chronic kidney disease.
  Variable adjusted odds ratio (95% ci) P value
Age ≥ 45 years 13.2 (3.1, 56) <0.001
Male sex 3.5 (1.6, 7.8) 0.002
Logistic regression Chi-squared = 37, P = <0.001
Hosmer–Lemeshow test Chi-squared = 3, P = 0.215
Area under ROC curve 0.80
CI, confidence interval; ROC receiver operating characteristics.
table 3.  Univariable analysis for risk factors of chronic kidney disease.
Variable cKD




Age ≥ 45 years
No 2 1030 1 (reference)
<0.001
Yes 26 935 14.3 (3.4, 60.5)
Male sex
No 10 1352 1 (reference)
<0.001
Yes 18 613 4 (1.8, 8.7)
Viral load ≥ 1000 copies/mL
No 27 1907 1 (reference)
0.848
Yes 1 58 1.2 (0.2, 9.1)
Treatment duration ≥ 108 months
No 12 991 1 (reference)
0.426
Yes 16 974 1.4 (0.6, 2.9)
CI, confidence interval; CKD, chronic kidney disease.
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lated the eGFR using the CKD-EPI equation, as is recom-
mended.
CKD occurrence rises with increasing age, and this has 
also been observed in HIV-infected populations [16,21,23]. 
We observed this association in our study. However, it is 
important to consider that age may also be a marker of 
the presence of HIV infection for a longer duration and of 
other comorbidities that are risk factors for CKD [25]. 
While being male was a risk factor for CKD in our study, 
other studies have demonstrated that there is no difference 
in the occurrence of CKD by sex [26]. However, kidney 
failure tends to be higher among men compared to 
women [26]. Establishing virological control through 
antiretroviral therapy is an important part of measures to 
reduce the occurrence of kidney disease in HIV, and a good 
response to antiretroviral therapy improves kidney function 
[10,27]. The proportion of participants in our study with 
virological control was 97% and this may explain the low 
prevalence we are reporting. Additionally, the prevalence 
of diabetes mellitus in the Namibian population, based on 
the 2013 Namibia Demographic and Health Survey, was 
low at 5.1% [28]. The low prevalence of an important 
determinant of CKD in the general population may also 
help explain the low prevalence of CKD we are reporting. 
strengths and limitations
The strengths of our study are that we carried out a 
multicentre study with a sample of 1 993 participants, used 
the recommended CKD-EPI equation, and we established 
chronicity. However, as we relied on existing records, we 
were not able to collect data on established risk factors for 
CKD such as diabetes mellitus and hypertension. We used 
only eGFR to diagnose CKD, and data on albuminuria/
proteinuria and abnormalities of kidney structure were not 
available. This may imply that we underestimated the 
prevalence of CKD in this population. Furthermore, we did 
not assess TDF use as a risk factor for CKD as patients 
with CKD are deliberately not given TDF-containing anti-
retroviral therapy, as per our guidelines. 
cONcLUsIONs
The burden of CKD among HIV-infected adults on anti-
retroviral therapy in northern Namibia was low at 1.4%. 
Since older age was established as a risk factor of CKD in 
this population, we recommend routine assessment of 
eGFR in older patients with HIV infection. 
supplementary materials
The characteristics of study participants and the excluded 
patients are available via the supplementary materials on 
the African Journal of Nephrology website.
cKD-EPI Equation
Female
eGFR = 144 × (serum creatinine/61.9)–0.329 × (0.993) 
^age if serum creatinine is less than or equal to 61.9 μmol/L 
[19].
eGFR = 144 × (serum creatinine/61.9) ^-1.209 × (0.993) 
^age if serum creatinine is greater than 61.9 μmol/L [19].
Male
eGFR = 141 × (serum creatinine/79.6) ^-0.411 × (0.993) 
^age if serum creatinine is less than or equal to 79.6 μmol/L 
[19].
eGFR = 141 × (serum creatinine/79.6) ^-1.209 × (0.993) 
^age if serum creatinine is greater than 79.6 μmol/L [19].
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